OWLMSPA

[OWLMSPA @OWLMSPA]

$MBRX who cares your lying daily show.

[Moleculin Biotech @moleculinbio]

Tune-in today, August 20th at 2 PM ET for Moleculin CEO Walter Klemp's presentation at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. Register here: https://t.co/WuNQRQsoS0 $MBRX

[OWLMSPA @OWLMSPA]

$MBRX ... sure but your recruiting development looks sad.

[Moleculin Biotech @moleculinbio]

Moleculin has secured approvals from both RAMPA in Georgia and the EU's EMA, boosting the profile of its Phase 2B/3 MIRACLE trial. Enrollment in Part A of MIRACLE has reached seven subjects treated and one additional subject in screening. Read more: https://t.co/hH8TAKMDd9 $MBRX

[OWLMSPA @OWLMSPA]

$MBRX Roth Capital ATM share program done!?

[Virtual Investor Co. @InvestorVirtual]

Wally Klemp, CEO of @moleculinbio, joins the Virtual Investor Summer Spotlight On Demand Conference to spotlight Moleculin’s progress in targeting hard-to-treat cancers and viral diseases.

Watch now: https://t.co/wqGoFyH6De
$MBRX

[OWLMSPA @OWLMSPA]

$MBRX this guy is retired ... how much you are paying for him ... uh "shareholder"

[Moleculin Biotech @moleculinbio]

Moleculin announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. Read more: https://t.co/FaAXYiljjf $MBRX

[OWLMSPA @OWLMSPA]

$MBRX You and your corrupt Roth Capital friends. S1/A closing in AH or PM tomorrow…!?

[Moleculin Biotech @moleculinbio]

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds: https://t.co/BPjiksG6FY $MBRX

[OWLMSPA @OWLMSPA]

$MBRX

[Moleculin Biotech @moleculinbio]

Read full comments from Walter Klemp, chairman and CEO of Moleculin, on the recent announcement of first country approval in Europe to begin recruiting for the MIRACLE Phase 3 pivotal trial for R/R #AcuteMyeloidLeukemia: https://t.co/bpRjyBILZO $MBRX #AML

[OWLMSPA @OWLMSPA]

$MBRX you want to pay $750k to close an offering… ! 😷

[Moleculin Biotech @moleculinbio]

Moleculin remains on track to treat first subject in its pivotal Ph.3 clinical trial in Q1 2025. A recently amended protocol accelerates unblinding of preliminary primary efficacy data & safety/tolerability for first 45 subjects, expected in H2 2025. https://t.co/bpRjyBILZO $MBRX

[OWLMSPA @OWLMSPA]

@moleculinbio $MBRX 👇

[OWLMSPA @OWLMSPA]

$MBRX S1 in tax selling season, why? You haven’t time to fill it in ‘25? Looks like you are snuggle with corrupt hedge funds to raise cash! 👇 Shame you

[OWLMSPA @OWLMSPA]

$MBRX S1 in tax selling season, why? You haven’t time to fill it in ‘25? Looks like you are snuggle with corrupt hedge funds to raise cash! 👇 Shame you

[Moleculin Biotech @moleculinbio]

From all of us at Moleculin, we wish you a joyful and restful holiday season.

#HappyHolidays!

[OWLMSPA @OWLMSPA]

$MBRX Max Performance -99% CEO in 2024 - it's time to invest in MBRX ... Sure or? When you are filling EFFECT of S1 to dilute retailers again, still this year? Shame on you, right?

[Moleculin Biotech @moleculinbio]

2024 has been a year of major milestones for Moleculin. We’re excited for what’s ahead as we continue to drive change in hard-to-treat tumors.

https://t.co/hE9RddFRPG
$MBRX #AML #Oncology

[OWLMSPA @OWLMSPA]

$MBRX Year performance -80% Great Job CEO + CFO = ?

[Moleculin Biotech @moleculinbio]

2024 has been a year of major milestones for Moleculin. We’re excited for what’s ahead as we continue to drive change in hard-to-treat tumors.

https://t.co/hE9RddFRPG
$MBRX #AML #Oncology

[Moleculin Biotech @moleculinbio]

Moleculin today announced the publication of its abstract, “Annamycin, a non-cardiotoxic anthracycline, demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML,” shared at the #ASH2024 Annual Meeting. https://t.co/JbHKbrscDZ $MBRX

[Moleculin Biotech @moleculinbio]

Discover more about our MIRACLE pivotal clinical trial in second-line #AcuteMyeloidLeukemia. We're excited to take this important step forward in advancing treatment options.

https://t.co/IXBgpDDihG
$MBRX #Oncology #AML

[Moleculin Biotech @moleculinbio]

Preclinical study shows Annamycin effectively targets both Cytarabine (Ara-C) and Venetoclax resistant acute myeloid leukemia cell lines from heavily pretreated R/R primary AML patients in vitro. For more details: https://t.co/JbHKbrscDZ #ASH2024 $MBRX

[Moleculin Biotech @moleculinbio]

Recent preclinical data shared at #ASH2024 appear to correlate with preliminary clinical data showing Annamycin in combo. w/ Ara-C achieving a 60% CRc rate in subjects who were R/R to Venetoclax as a first line therapy. Read more: https://t.co/JbHKbrscDZ $MBRX

[Moleculin Biotech @moleculinbio]

The lack of apparent cardiotoxicity, improved organotropism, synergy w/ Ara-C, and possible immune-memory reinforcing properties appear to contribute to Annamycin's favorable performance. For more on our recent preclinical data: https://t.co/JbHKbrscDZ $MBRX #ASH2024

[Moleculin Biotech @moleculinbio]

Giovanni Martinelli, MD, member of Moleculin's Scientific Advisory Board, and CEO Walter Klemp comment on the abstract publication of preclinical data demonstrating significant activity of Annamycin in Venetoclax resistant AML: https://t.co/JbHKbrscDZ $MBRX #ASH2024

[Moleculin Biotech @moleculinbio]

#InCaseYouMissedIt: We hosted a KOL webcast featuring valuable insights on #AcuteMyeloidLeukemia with esteemed experts—Dr. Michael Andreef, Dr. Giovanni Martinelli, and Dr. Mohamad Cherry, MD. Watch the full replay here: https://t.co/pXZ86oujd4

$MBRX

[OWLMSPA @OWLMSPA]

$MBRX

[Moleculin Biotech @moleculinbio]

$MBRX is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses. https://t.co/hE9RddFRPG

#Oncology #AcuteMyeloidLeukemia #SoftTissueSarcoma

[OWLMSPA @OWLMSPA]

$MBRX @ CFO 10-Q what a shame … Hoping you will never get a company as CFO

[Moleculin Biotech @moleculinbio]

#ICYMI - Moleculin team hosted a webcast to discuss recently announced plans for the Phase 3 miracle pivotal trial for the treatment of R/R #AcuteMyeloidLeukemia. Listen to a replay here: https://t.co/xAR9tLk8r5 $MBRX #AML